Hemophilia Treatment Market By Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals, and Others), and By Region - Trends, Analysis and Forecast till 2030

The market for hemophilia treatments was valued at US$12.45 billion in 2020 and is projected to grow at a compound annual growth rate of 6.1% to reach US$22.41 billion by 2030.

An uncommon inherited genetic disorder called hemophilia impairs the blood's capacity to clot after an injury or bleeding episode. Patients with hemophilia experience lengthier episodes of bleeding than usual because their blood doesn't contain as many clotting factors as it should. Hemophilia A and B are the two primary types of hemophilia. A deficit of clotting factor VIII causes Hemophilia A, while a deficiency of clotting factor IX causes hemophilia B. Genetically modified clotting factor medications, which prevent and treat prolonged bleeding, are typically used to treat hemophilia. According to the Centers for Disease Control and Prevention, around 400 newborns are born with hemophilia a year, and hemophilia affects 1 in 5,000 male births. As stated by the identical source, There are thought to be 20,000 or so hemophiliacs in the United States.